Rebuttal and response to: "The efficacy and tolerability issue of generics of imatinib in the treatment of chronic myeloid leukemia: do generics really jeopardize patient safety?" by Ahmet Emre Eskazan, Muhlis Cem Ar and Teoman Soysal.
Alaa Fadhil Alwan
Leukemia & lymphoma
View on PubMed
Abstract & Figures
Sorry, we couldn't extract an abstract for this paper.
Myeloid Leukemia, Chronic
Sorry, we couldn't extract any citations for this paper.
Sorry, we couldn't extract any references for this paper.
Loading similar papers…
Presentations referencing similar topics